Abstract: A group of tropomyosin receptor kinase inhibitors including an amido-phenoxy-indazole structure fragment. These compounds show potent inhibitory effects on various oncogenic kinases, especially TRK, and thus can be used to treat tumors or cancers.
Type:
Grant
Filed:
September 3, 2019
Date of Patent:
April 9, 2024
Assignee:
TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED
Inventors:
Boyu Zhong, Tony Yantao Zhang, Yiju Cao, Guangming Chen
Abstract: Provided are methods for prophylaxis or therapy for an RNA virus infection. The methods involve modulating the Type I interferon pathway in RNA virus infected cells of an individual. The Type I interferon pathway is modulated by administering one or more agents to virus infected cells that inhibit the expression and/or function of METTL3 or inhibit expression and/or function of YTHDF1, YTHDF2 or YTHDF3.
Abstract: Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods of using the pharmaceutical compositions to desensitize TRPV1 receptors in order to treat pain, cardiovascular diseases such as cardiac hypertrophy, overactive bladder, and chronic cough.
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
Type:
Grant
Filed:
May 3, 2022
Date of Patent:
April 2, 2024
Assignee:
EISAI R&D MANAGEMENT CO., LTD.
Inventors:
Ermira Pazolli, Silvia Buonamici, Thiwanka Samarakoon, Sudeep Prajapati, Nathan Fishkin, James Palacino, Michael Seiler, Ping Zhu, Andrew Cook, Peter Smith, Xiang Liu, Shelby Ellery, Dominic Reynolds, Lihua Yu, Zhenhua Wu, Shouyong Peng, Nicholas Calandra, Megan Sheehan, Yonghong Xiao
Abstract: The present invention relates to a pharmaceutically compatible iron chelator or a prodrug thereof for use in treating and/or preventing cancer in a subject suspected or known to comprise hypoxic cancer cells, and use in treatment and/or prevention of a human papillomavirus (HPV) related lesion. The present invention further relates to a use of an iron chelator or prodrug thereof for inducing senescence in a cancer cell, preferably a hypoxic cancer cell; and to a method for inducing an irreversible proliferation arrest in cancer cells comprising a) contacting said cancer cells with an iron chelator or prodrug thereof and, thereby, b) inducing an irreversible proliferation arrest in said cancer cells.
Type:
Grant
Filed:
November 23, 2018
Date of Patent:
March 19, 2024
Assignee:
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Inventors:
Felix Hoppe-Seyler, Julia A. Braun, Karin Hoppe-Seyler
Abstract: The invention relates to a (S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a substance as a colloid of fine solid and/or liquid particles in a fluid. 1. According to the invention the substance is dispensed in form of a parenteral administration into a human and/or animal body.
Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
Type:
Grant
Filed:
April 23, 2021
Date of Patent:
March 5, 2024
Assignee:
VALO HEALTH, INC.
Inventors:
Kenneth W. Bair, Nicholas Barczak, Bingsong Han, David R. Lancia, Jr., Cuixian Liu, Matthew W. Martin, Pui Yee Ng, Aleksandra Rudnitskaya, Jennifer R. Thomason, Mary-Margaret Zablocki, Xiaozhang Zheng
Abstract: Disclosed herein are methods of treating a cancer characterized by expressing a mutant form of a RAS protein. Some embodiments relate to treatment of cancer by administering Plinabulin to a subject in need thereof.
Abstract: A 2-(benzo[d]oxazol-2-yl)-N?-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)acetimidamide compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
October 10, 2023
Date of Patent:
February 27, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ?3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.
Abstract: A N?-[(4-chlorobenzoyl)oxy]-1,3-benzothiazole-2-carboximidamide compound, its synthesis, and its use as an anticancer and/or antimicrobial agent.
Type:
Grant
Filed:
August 29, 2023
Date of Patent:
February 27, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer, Doaa H. Ahmed
Abstract: Described herein are methods of treating metastatic castration-sensitive prostate cancer with anti-androgens, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.
Abstract: The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a diseaseas a sole agent or in combination with other active ingredients.
Type:
Grant
Filed:
December 18, 2017
Date of Patent:
February 20, 2024
Assignee:
BAYER PHARMA AKTIENGESELLSCHAFT
Inventors:
Stefan Baeurle, Adam James Davenport, Christopher Stimson, Jens Nagel, Nicole Schmidt, Andrea Rotgeri, Ina Groeticke, Alexandra Rausch, Juergen Klar, Thomas Dyrks
Abstract: The present specification provides improved methods of treating Her2+ cancers in which an RXR agonist and a taxane are administered to a subject having a Her2+ cancer. Thyroid hormone and other anticancer agents may also be administered. Related compositions and combination are also disclosed.
Type:
Grant
Filed:
December 7, 2022
Date of Patent:
February 13, 2024
Assignees:
Io Therapeutics, Inc., Board of Regents, The University of Texas System
Inventors:
Martin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar